文献速递胸部肿瘤放疗放疗物理与技术

非小细胞肺癌患者中EGFR酪氨酸激酶抑制剂联合胸部放疗的治疗相关肺炎:系统综述与Meta分析

Treatment-Related Pneumonitis of EGFR Tyrosine Kinase Inhibitors Plus Thoracic Radiation Therapy in Patients With Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-09-14

该系统综述与Meta分析纳入37项研究共1143例非小细胞肺癌患者,评估胸部放疗联合EGFR酪氨酸激酶抑制剂(TKI)的治疗相关肺炎(TRP)风险。总体3级及以上严重TRP发生率为3.8%(95%CI 1.8%-6.5%),致死性肺炎罕见为0.1%(95%CI 0.0%-0.3%)。同步TKI与放疗的严重TRP率为4.9%(95%CI 2.4%-8.1%),显著高于序贯治疗的0.4%(95%CI 0.0%-3.1%)。

要点

  • 总体严重TRP发生率3.8%,致死性肺炎0.1%,风险可接受。
  • 同步TKI与放疗严重TRP率4.9%,显著高于序贯治疗0.4%。
  • 同步治疗耐受性较差,应谨慎给药;奥希替尼数据有限需进一步研究。

核心结论

  • 胸部放疗联合EGFR-TKI治疗在非小细胞肺癌患者中严重TRP风险可接受且死亡率罕见。
  • 同步治疗耐受性较差,应谨慎给药。
  • 需进一步研究奥希替尼,因其数据有限。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed-MEDLINE和Embase数据库,纳入37项合格研究共1143例患者。
  • 提取3级及以上严重TRP病例数,采用固定或随机模型Meta分析,使用I²和τ²统计量进行异质性检验。
  • 对放疗类型和联合治疗顺序进行亚组分析。

主要发现

  • 总体严重TRP发生率为3.8%(95%CI 1.8%-6.5%),致死性肺炎罕见为0.1%(95%CI 0.0%-0.3%)。
  • 根治性(化)放疗亚组严重TRP比例为2.3%(95%CI 1.0%-4.1%,19项研究,n=702),立体定向体部放疗或姑息放疗亚组为2.9%(95%CI 1.3%-5.1%,15项研究,n=361)。
  • 同步TKI与放疗严重TRP率为4.9%(95%CI 2.4%-8.1%,26项研究,n=765),显著高于序贯治疗的0.4%(95%CI 0.0%-3.1%,6项研究,n=200)。

临床怎么用

  • 作者认为同步TKI与胸部放疗耐受性较差,应谨慎给药。
  • 作者指出需进一步研究奥希替尼,因其数据有限。

局限性

  • 需进一步研究奥希替尼,因其数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thoracic radiation therapy (RT) for non-small cell lung cancers may overcome resistance to tyrosine kinase inhibitors (TKIs). However, the risk of severe treatment-related pneumonitis (TRP) is a major concern, and the results of the combined treatment remain controversial. Therefore, we aimed to systematically review existing publications and provide a meta-analysis of TRP from a combined therapy of thoracic RT and TKIs. A systematic literature review was performed using the PubMed-MEDLINE and Embase databases to identify eligible publications. The number of severe TRP cases of grade 3 or higher was extracted and then analyzed by fixed or randomized model meta-analysis. Heterogeneity tests were performed using the I² and τ² statistics. Subgroup analyses were conducted on the types of RT and the sequence of the combined treatment. Our literature search identified 37 eligible studies with 1143 patients. Severe TRP occurred in 3.8% (95% CI, 1.8%-6.5%) of patients overall, and fatal pneumonitis occurred rarely in 0.1% (95% CI, 0.0%-0.3%). In the subgroup analysis, the severe TRP proportion was 2.3% (95% CI, 1.0%-4.1%) for patients under definitive (chemo)RT (19 studies, n = 702) versus 2.9% (95% CI, 1.3%-5.1%) for patients who received local stereotactic body RT or palliative RT (15 studies, n = 361). The severe TRP rate was 4.9% (95% CI, 2.4%-8.1%) for concurrent TKI and RT (26 studies, n = 765), which was significantly higher than TRP of 0.4% (95% CI, 0.0%-3.1%) for sequential therapy (6 studies, n = 200). Our meta-analysis showed that combined thoracic RT and epidermal growth factor receptor-TKI therapy has an acceptable risk of severe TRP and rare mortality in patients with non-small cell lung cancers. Concurrent treatment is less tolerable and should be administered with caution. Further investigations using osimertinib are required as the data on its effects are limited.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Meng Y, Sun H, Wang S, et al. Treatment-Related Pneumonitis of EGFR Tyrosine Kinase Inhibitors Plus Thoracic Radiation Therapy in Patients With Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Int J Radiat Oncol Biol Phys. 2023. PMID: 37716460. doi:10.1016/j.ijrobp.2023.09.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。